Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females at least 18 years of age~2. Diagnosis of functional homozygous FH by at least one (a-c) of the following clinical criteria:~   * documented functional mutation(s) in both LDL receptor alleles or alleles known to affect LDL receptor functionality OR~  * skin fibroblast LDL receptor activity less than 20% normal OR~  * untreated TC greater than 500 mg/dL AND TG less then 300 mg/dL AND both parents have documented TC greater than 250 mg/dL~3. Concurrent lipid lowering medication/apheresis must be stable for at least 6 weeks before the baseline visit and must remain stable for the first 26 weeks.~4. Body weight at least 40 kg and less than 136 kg~5. Negative screening pregnancy test if female of child-bearing potential (females of child-bearing potential and all males must be following a medically accepted form of contraception)~6. Subjects must be willing to comply with all study-related procedures~Exclusion Criteria:~1. Uncontrolled hypertension~2. History of chronic renal insufficiency~3. History of biopsy proven cirrhosis or abnormal LFTs at screening (AST or ALT greater than 2 x upper limit of normal and/or Total Bilirubin greater than or equal to 1.5 mg/dl unless patient has unconjugated hyperbilirubinemia due to Gilbert's syndrome)~4. Chronic hepatitis B or chronic hepatitis C~5. Any major surgical procedure occurring less than 3 months prior to the screening visit~6. Cardiac insufficiency defined by the NYHA classification as functional Class III or Class IV~7. Previous organ transplantation~8. History of a non-skin malignancy within the previous 3 years~9. Male subjects reporting more than 2 drinks per day or females reporting more than 1 drink per day (1 drink= 12 oz beer, 1 oz hard liquor, 5 oz wine).~10. Participation in an investigational drug study within 6 weeks prior to the screening visit~11. Known significant gastrointestinal bowel disease or malabsorption such as inflammatory bowel disease or chronic pancreatitis requiring use of daily pancreatic enzymes.~12. Serious or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study.~13. Certain prohibited medications known to be potentially hepatotoxic, especially those that can induce microvesicular or macrovesicular steatosis. These include but are not limited to: accutane, amiodarone, heavy acetaminophen use (4g/day greater than 3 x q week), methotrexate, tetracyclines,and tamoxifen~14. Documented diagnosis of any of the following pulmonary conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Idiopathic pulmonary fibrosis~15. Documented diagnosis of any of the following liver diseases: Nonalcoholic Steatohepatitis, Alcoholic liver disease, Autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson's disease, hemochromatosis, alpha 1 anti-trypsin deficiency.~16. Current use of corticosteroids or betaine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AEGR-733 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).